Swedish Orphan Biovitrum (OTCMKTS:BIOVF) AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.
The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions. Sobi also holds commercialization rights to Synagis (palivizumab) for the prevention of severe respiratory syncytial virus in infants under agreements with AstraZeneca. In addition to these flagship products, the firm maintains a diverse pipeline of biologics, small molecules and orphan drug candidates in various stages of clinical development.
Sobi operates through a network of subsidiaries and partnerships across Europe, North America and selected international markets. The company’s commercial infrastructure includes direct sales forces in key regions and collaborations with pharmaceutical partners to extend geographic reach. Manufacturing is anchored by facilities in Sweden and strategic contract‐manufacturing organizations, ensuring consistent supply of high‐complexity biologics and specialty pharmaceuticals to hospitals and specialty clinics worldwide.
Under the leadership of President and CEO Guido Oelkers, Sobi continues to pursue strategic acquisitions and licensing deals to expand its portfolio in rare disease areas. With a research and development center in Stockholm and ongoing investments in clinical trials, the company aims to deliver new therapeutic options for patients with limited treatment choices, reinforcing its position as a dedicated rare disease specialist in the global biopharmaceutical industry.
